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A B S T R A C T
Background: Stem cell regeneration is the holy grail of meniscal tissue repair. Currently, the best treatment is to
preserve the original meniscus but if it fails, a partial meniscectomy is indicated to delay the onset of osteoar-
thritis.
Materials and methods: The authors present a systematic review to determine the up-to-date evidence underlying
the use of mesenchymal stem cells for meniscal regeneration in humans. A search was conducted using the
electronic databases of MEDLINE/Pubmed, Google scholar, and the Cochrane Collaboration. Search keywords
included human, meniscus, stem cells and regeneration.
Results: After screening 10 non-duplicate studies, 5 were identiﬁed based on title and abstract. 4 were included
in the analysis. There were marked diﬀerences in the method of stem cell harvest techniques. 3 studies ad-
ministered stem cells through percutaneous injection into the knee and 1 study used a collagen scaﬀold. MRI
analysis, functional scores and safety were assessed and the longest follow-up period was 2 years. The Visual
Analogue Score (VAS) was most commonly used to assess function and patients generally showed an im-
provement. There were no reported adverse events.
Conclusion: Despite positive results from animal models, there is currently a lack of evidence in humans to
conclude that stem cells can form durable neotissue similar to original human meniscus. There is a need for
standardisation of protocol before further trials are considered. Initial outcomes from human studies are pro-
mising and mesenchymal stem cells may play an important role in meniscal repair in years to come.
1. Background
The holy grail of meniscal repair lies within the realms of meniscal
regeneration. Most meniscal injuries are associated with a more active
lifestyle and the damage of meniscal tissue renders young patients at a
higher risk of undergoing meniscal surgery and hence osteoarthritis [1].
Established options for the management of a torn meniscus include
partial or complete meniscectomy, meniscal allograft transplantation
and synthetic meniscus transplantation. Other more conservative op-
tions include conduit treatment, abrasion therapy, platelet-rich-plasma
therapy and more recently, meniscus tissue engineering [2]. Tissue
engineering involves the use of cells with regenerative potential to
augment the healing process following a meniscal injury. Cells that
have been studied include articular chondrocytes, meniscal ﬁbrochon-
drocytes, and mesenchymal stem cells (MSCs) [2]. Within orthopaedics,
MSCs are mainly derived from bone marrow. However, other sources
include synovial membrane [3], adipose tissue [4], meniscus-derived
MSCs [4] and extra-articular tissues such as dermis [5]. Adult MSCs are
particularly attractive due to their potential for multilineage diﬀer-
entiation, immunomodulation and ability to migrate towards sites of
injury [6]. One concern regarding MSCs is that the cartilage formed
from MSCs has diﬀerent mechanical properties to native meniscal tissue
and inferior content in the extracellular matrix [6]. Further questions
yet to be deﬁnitively answered include the optimal delivery method
and scaﬀold choice [7].
A large volume of pre-clinical data exists, and stem cells in meniscal
regeneration have been widely studied in animal models. Few studies,
however, have assessed the in-vivo use of MSCs in human meniscal
injuries. Limited understanding of the interplay between MSCs and
stimulatory factors involved in meniscal regeneration is currently one
of the factors contributing to regulatory burdens and their limited
clinical use [8].
In this review, we explore the current studies which investigate the
use of MSCs for meniscal regeneration in humans. Our objectives were:
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to determine the eﬃcacy of using human mesenchymal stem cells to
repair damaged meniscus; to critically review all studies to date in-
volving the application of mesenchymal stem cells into the human adult
knee joint and to identify improvements for future human studies.
2. Materials and methods
A systematic review of literature for meniscal regeneration in the
human model was performed and reported according to the PRISMA
criteria (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) [9]. Searches were carried out on 1st July 2017 of MEDLINE/
Pubmed and Google Scholar using the following search string: Human
AND (meniscal OR meniscus OR menisci OR knee) AND (tear OR in-
jury) AND (stem cell OR mesenchymal OR MSC). The inclusion period
was January 1st, 2000 to July 1st, 2017 (see Fig. 1).
Studies were then screened by title and abstract using the following
inclusion criteria:
1. Mesenchymal stem cells used for meniscus repair, tested in human
models only regardless of how cells were extracted or delivered.
2. Participants of any age, any nationality, male or female were in-
cluded.
3. Participants must also have had MRI evidence of meniscal degen-
eration, meniscal tear or osteoarthritis, pre-stem cell application.
Studies involving the application of human stem cells in animal
models, in-vitro experiments, reviews, articles in languages other than
English and articles with missing full texts were excluded. Each study
was independently reviewed by the authors RP and EC, with relevant
details recorded on a data extraction sheet.
3. Results
A total of 45 studies from MEDLINE, 55 studies from Google Scholar
and 1 study from the Cochrane Collaboration were obtained from the
literature search. After excluding 89 duplicated results and 2 non-
English studies, 10 studies were analysed using their title and abstract,
of which 5 studies were excluded as they involved the application of
human stem cells in animal models. The full text of the remaining 5
articles were screened and 1 study was excluded as it was a study as-
sessing the safety of stem cell administration. A total of 4 studies met
the inclusion criteria in this review amounting to a total of 67 patients.
2 studies were case reports [10,11], 1 study was a case series [12] and 1
study was a double-blind randomized control trial [13]. The average
patient age was 38. Gender distribution generally had more males than
females. Table 1 outlines the methods of extraction and delivery of stem
cells and Table 2 summarises the objectives and results of each study.
3.1. Method of obtaining stem cells
Vangsness Jr et al.’s study used a preparation of ex-vivo cultured
adult human mesenchymal stem cells derived from bone-marrow as-
pirates, obtained from unrelated donors who were not human leukocyte
antigen (HLA)-matched to recipients. The donors were also between 18
Fig. 1. PRISMA 2009 ﬂow diagram.
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and 30 years of age which diﬀered from the average age of the recipient
population. Jaewoo Pak et al. obtained stem cells from adipose tissue
extracted by liposuction of the subcutaneous layer of the lower ab-
dominal area. The stem cells were then separated from the lipoaspirates
by a fat stem cell isolator after treatment with collagenase within the
operating room and injected into the patient's aﬀected knee. Centeno CJ
et al. and Whitehouse MR et al.’s studies were the only studies to use
bone marrow-derived stem cells from the patient. This was performed
as a separate operation and bone marrow was obtained from the iliac
crest. The stem cells were cultured to the third passage before being
administered to the patient in Centeno CJ et al.’s study but Whitehouse
MR et al.’s study showed no evidence of tumour forming potential at
either passage 0 or 2.
3.2. Method of stem cell administration
Whitehouse MR et al.’s study was the only study to have used a
collagen scaﬀold seeded with mesenchymal stem cells to repair the torn
meniscus. All other studies used an intra-articular approach of percu-
taneously injecting stem cells into the aﬀected knee joint.
3.3. MRI analysis
In Vangsness Jr et al.’s study, the formulated treatment for stem cell
injection consisted of 50 × 106 cells (Group A), 150 × 106 cells (Group
B) or the vehicle control (control group). At six months, an increase in
meniscus volume of> 15% was observed in two patients, one each in
groups A and B. At twelve months, four patients in Group A met the
threshold of increase in meniscal volume. It is also mentioned that the
control group compared with Group A and the overall group compar-
ison (A + B) were signiﬁcant at twelve months in terms of the pro-
portion of patients meeting the criteria. At two years, three patients in
Group A demonstrated an increase in meniscus volume of> 15% and
the combined group comparison (A + B) with controls remained sig-
niﬁcant. At no time point was the criterion achieved in any of the pa-
tients in the control group. Centeno CJ et al.’s study also showed an
increase in meniscus volume at one and three months. Jaewoo Pak
et al.’s study only had one MRI at three months which showed a healed
meniscus but the patient refused to undergo further post-procedure
MRIs due to symptom improvement and ﬁnancial reasons. Whitehouse
MR et al.’s study was the only study that did not measure meniscal
thickness. However, for 3 out the 5 subjects MRI did show that the
menisci had not displaced and the initial abnormally high signal was
diminishing with time after 12 months.
3.4. Functional scores
VAS and functional scores were reported in all 4 studies. In Centeno
CJ et al.’s study, at three month follow-up modiﬁed VAS scores de-
creased from 3.33 to 0.13. Jaewoo Pak et al.’s study also had an as-
sessment period of 3 months. Before the procedure, the patient had
moderate pain (VAS score of 5) at rest and increased pain when walking
(VAS walking index of 7), which all improved post-treatment. The study
also reported an improvement of symptoms 18 months after treatment
based on a telephone questionnaire. In Whitehouse MR et al.’s study the
treatment failed in 2 patients who subsequently developed pain, swel-
ling and locking in the knee at around 15 months leading to treatment
with meniscectomy. The ﬁrst case had a repeat tear at the site of repair
and the second case had incomplete healing of the tear. Both patients
started with a slightly lower baseline Tegner-Lysholm score and range
of motion. In contrast, the remaining patients who were successfully
treated showed improvements in all clinical scores over the ﬁrst 12
months and these changes were maintained between 12 and 24 months.
In Vangsness Jr et al.’s study, knee pain was assessed using a VAS tool
and the Tegner-Lysholm knee score. Overall, VAS pain scores decreased
signiﬁcantly for patients post-surgery compared with baseline values
Table 1
Methods of extraction and delivery of MSCs.
Year Author Type of study Method of obtaining MSCs Method of delivery of MSCs
2008 Centeno CJ et al. Case Control Bone marrow aspiration from the iliac crest. Percutaneous injection into knee.
2014 Jaewoo Pak et al. Case Control Liposuction of the subcutaneous layer of the lower abdominal area. Percutaneous injection into knee.
2014 Vangsness CT Jr et al. Randomized controlled
trial
Preparation of ex vivo cultured adult human mesenchymal stem cells derived
from bone-marrow aspirates obtained from unrelated donors
Percutaneous injection into knee.




Year Author Objectives Results
2008 Centeno CJ et al. Pre- and post-treatment subjective VAS pain scores, physical
therapy assessments, and MRIs
At 24 weeks post-injection, the patient had statistically signiﬁcant cartilage and
meniscus growth on MRI, as well as increased range of motion and decreased
modiﬁed VAS pain scores.
2014 Jaewoo Pak et al. Pre- and post-treatment VAS walking index, Functional rating
index, range of motion and MRI
Three months after the treatment, the patient's symptoms improved. Repeated MRI
showed almost complete disappearance of the torn meniscus.
2014 Vangsness CT Jr et al. Patients were randomized to one of three treatment groups:
Group A- Injection of 50 × 106 allogeneic MSC
Group B- 150 × 106 allogeneic MSC and the
Control group- sodium hyaluronate vehicle control.
Evaluate safety, meniscus regeneration, overall condition of
the knee joint, and clinical outcomes at intervals through two
years.
No ectopic tissue formation or clinically important safety issues were identiﬁed.
There was signiﬁcantly increased meniscal volume (deﬁned a priori as a 15%
threshold) determined by quantitative MRI in 24% of patients in Group A and 6%
in Group B at twelve months post meniscectomy (p = 0.022). No patients in the
control group met the 15% threshold for increased meniscal volume. Patients with
osteoarthritic changes who received mesenchymal stem cells experienced a
signiﬁcant reduction in pain compared with those who received the control, on the
basis of VAS assessments.
2017 Whitehouse MR et al. Pre- and post-treatment IKDC and Tegner-Lysholm scores,
range of motion and MRIs
3 out of the 5 patients had a successful outcome at 24 months showing
improvements in all clinical scores over the ﬁrst 12 months. Out of the 2 patients
with failed implants, 1 had a tear at the implant site and the other had incomplete
healing of the meniscus. These 2 patients showed no improvement in clinical
scores between the 6–12 month period but had lower baseline Tegner-Lysholm
scores compared to the other patients.
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for all treatment groups. In patients with osteoarthritic changes at the
time of surgery, improvement relative to the vehicle control was also
observed for both groups A and B. Signiﬁcant diﬀerences from the
control were observed at two years for Group A and at one year and two
years for Group B. Patients improved in their Tegner-Lysholm knee
scale scores relative to the baseline at all time points.
3.5. Adverse eﬀects and safety
No adverse events or clinically important safety issues were re-
ported in any of the studies.
4. Discussion
It is diﬃcult to make strong conclusions from the 3 case reports. Of
note, Pak et al. and Whitehouse MR et al. investigated the eﬀects of
MSCs with relevance to meniscal repair, but Centeno et al.’s patient had
evidence of osteoarthritis [14]. In the 2 case reports [6,9], a short
follow up period of 3 months was used for MRI assessment, though Pak
et al. conducted telephone follow up 18 months post-procedure.
Nonetheless, excluding the studies by Vangsness et al. and Whitehouse
MR et al., long term follow-up data to assess the eﬃcacy and safety of
MSCs in meniscal repair is lacking.
Post-procedure biopsies to histologically assess the nature of the
regenerated tissue was also not performed in all three cases and may
represent an obstacle which needs to be overcome in future studies.
Visual analogue scores and functional rating scores were used as out-
come endpoints in both studies. However, an internationally-accepted
knee scoring system may lend greater validity and reliability to future
studies. One such score is the WOMAC Osteoarthritis Index which is
accepted as a reliable measure of knee function, pain and stiﬀness [15].
The type of stem cell used and the methods of extraction diﬀered
signiﬁcantly between the four studies. Pak et al. and Centeno et al.
injected platelet-rich plasma (PRP) and dexamethasone in addition to
stem cells. Pak et al. also included hyaluronic acid in their preparation.
The presence of additional components makes it diﬃcult to attribute
the clinical improvements solely to stem cell–derived tissue, although it
should be noted that in the case reported by Pak et al. the patient had
received previous injections of PRP and hyaluronic acid with no clinical
improvement. A randomized controlled trial would be necessary to
make any conclusions on whether injecting stem cells is superior to the
application of a scaﬀold in a human model.
The characteristics of the meniscal tear in the case reported by Pak
et al. were not discussed. However, Whitehouse MR et al.’s study did
emphasise that the meniscal tears were in the avascular zone. In future
studies this information will be important in understanding the poten-
tial of MSCs in the repair of the diﬀerent types of meniscal tear. Thus it
will be important that conclusions drawn from future studies take the
characteristics of the tear into account.
All 3 case studies reinforce the short-term safety of using me-
senchymal stem cells. However, as isolated case reports, they clearly
provide limited information.
To date, Vangsness et al.’s study is the only level 1 study investigating
the injection of allogenic MSCs in meniscal regeneration post-subtotal
meniscectomy. The authors conclude that there was evidence of meniscal
regeneration in the 2 groups treated with MSCs. However, closer analysis
of the results showed that out of 35 patients only 5 had an increased
meniscal volume>15% at one year and this decreased to 3 patients over
two years. Even though this was statistically signiﬁcant, the clinical re-
levance is questionable. Furthermore, compared to some animal studies
with a 2 year follow up [16], the decrease in meniscal regeneration could
either suggest a short-term eﬀect or variability in quantifying the me-
niscal volume on MRI. The type of stem cells used also weakens this
study as they were pooled from unrelated donors and there was no
mention of how they were obtained, which raises doubts on the plur-
ipotency and quality of the cells.
Notably, long term pain improved in patients who had MSCs com-
pared to controls [17]. The greatest improvement was observed in the
group given the highest dose of MSCs, which could suggest a dose-de-
pendent eﬀect. However, the study does not quantify the extent of os-
teoarthritis across the groups. Additionally, patients within the control
group had a BMI of more than 10 points lower than treatment groups,
suggesting that the extent of osteoarthritis in the control group may be
lower. There were also fewer patients with osteoarthritis in the control
group (7 patients compared to 11 and 12 in the other two groups)
which limits the comparison of outcomes.
It is undeniable that this level 1 study shows the safety of MSCs in
treating meniscal injuries.
Limitations of the review include a small number of human studies,
a lack of high quality studies and the included studies being in-
comparable due to variability in types of stem cells used and adminis-
tration methods. These studies have shown that despite success in an-
imal models [7], translational research in this area would need to
consider more than just the eﬃcacy of stem cells in meniscal repair.
Consensus must be reached on how MSCs are obtained and their
cost-eﬀectiveness. Jaewoo Pak et al. used liposuction to obtain stem
cells in a separate operation before administration of stem cells. This
would undoubtedly be a costly procedure both in terms of time and
money. The ideal scenario would be harvesting and implanting stem
cells in the least invasive way, making synovial membrane stem cells an
attractive option. However, animal models have shown that synovium
contains only a small amount of multipotent colony-forming cells [18]
and bone marrow derived stem cells might be a more practical choice as
they show larger cell numbers per colony [19]. This further raises the
question on the best method of delivery, including scaﬀolds and direct
knee injections. This is a widely debated topic and to date, no pre-
clinical studies have compared the eﬀectiveness of cell-scaﬀold com-
binations to the use of cells alone. Most importantly, the viability of
newly formed neo-tissue needs to be assessed in longer term human
studies. However, the current evidence suggests that stem cell therapy
for meniscal repair in humans can be safely conducted, paving the way
for more studies in the future.
5. Conclusion
Stem cells represent an exciting and attractive prospect in the
treatment of meniscal injuries. Despite good results in animal studies, it
remains in the early stages for humans. More studies need to be per-
formed before a reliable assessment can be made. However, the limited
number of human studies have suggested that stem cells do have po-
tential to undergo meniscal regeneration in humans and there is reason
to be optimistic for the future.
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